Skip to main content

Table 2 Baseline characteristics of 193 ever-smokers with locoregionally advanced nasopharyngeal carcinoma

From: The impact of smoking on the clinical outcome of locoregionally advanced nasopharyngeal carcinoma after chemoradiotherapy

  Light, short-term Light, long-term Heavy, short-term Heavy, long-term P value
  32(16.8%) 18(8.4%) 57(29.8%) 86(45.0%)  
Age, yr, median 40(20-58) 50(36-60) 39(24-59) 49(10-66) 0.452
Gender      0.005
Female 1(3.1) 1(12.5) 0 0  
Male 31(96.9) 17(87.5) 57(100) 86(100)  
T stage      0.368
1-2 7(21.9) 1(5.6) 8(14.0) 13(15.1)  
3-4 25(78.1) 17(94.4) 49(86.0) 73(84.9)  
N stage      0.463
0-1 16(48.5) 6(33.3) 25(43.9) 45(52.3)  
2-3 17(51.5) 12(66.7) 32(56.1) 41(47.7)  
Clinical stage      0.189
3 15(46.9) 14(75.0) 34(59.6) 43(50.0)  
4 17(53.1) 4(25.0) 23(40.4) 43(50.0)  
Treatment arm      0.641
IC + CCRT 16(50.0) 11(61.1) 32(56.1) 41(47.7)  
IC + RT 16(50.0) 7(38.9) 25(43.9) 45(52.3)  
RT dose(Gy),median(range) 72(68-78) 72(68-78) 72(68-78) 72(68-78) 0.118
CT course, median(range) 2(2-5) 32(1-5) 22(1-5) 22(1-5) 0.470
RT interruption      
Yes 2(6.2) 0(0) 1(1.8) 1(1.2) 0.337
No 30(93.8) 18(100) 55(98.2) 85(98.8)  
AMT      0.731
1-2 30(93.8) 18(100) 52(92.9) 80(93.0)  
3-4 2(6.2) 0(0) 4(7.1) 6(7.0)  
VCA-IgA      0.330
Positive(≥1:80) 30(93.8) 17(94.4) 47(83.9) 79(91.9)  
Negative 2(6.3) 1(5.6) 9(16.1) 7(8.1)  
EA-IgA      0.121
Positive(≥1:10) 27(84.4) 17(94.4) 39(69.6) 67(77.9)  
Negative 5(15.6) 1(5.6) 17(30.4) 19(22.1)  
Median follow-up yr (range) 6.8(0.5-8.7) 6.9(1.1-8.3) 6.5(0.2-8.6) 6.2(0.6-9.0) 0.572
  1. Abbreviations: IC + CCRT = induction chemotherapy plus concurrent chemoradiotherapy and IC + RT = induction chemotherapy plus radiotherapy. AMT = Acute mucosal toxicity.